Radiopharmaceutical Indications Need Not Be Disease-Specific - Final Rule
This article was originally published in The Gray Sheet
Executive Summary
FDA's final rule on "Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring," allows sponsors to propose indications that refer to a "biochemical, physiological, anatomical, or pathological process or to more than one disease or condition" in cases where the radiopharmaceutical "is not intended to provide disease-specific information."
You may also be interested in...
FDA issues imaging drug guidance
Recommendations on assessing imaging agent safety, designing clinical development programs and tailoring them to reflect the use of the agents are outlined in guidance titled "Developing Medical Imaging Drug and Biological Products," which addresses contrast agents and diagnostic radiopharmaceuticals in various imaging modalities, including CT, MRI, SPECT and PET. The guidance originally was released in 1998 as a single draft document to address in vivo radiopharmaceuticals for diagnostic and monitoring use (1"The Gray Sheet" May 24, 1999, p. 9). In 2003, the draft was divided into three sections to make it more user-friendly...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.